Details of Disease

Disease Name

Primary cutaneous peripheral T-cell lymphoma not otherwise specified

primary cutaneous unspecified peripheral T-cell lymphoma

Disease Hierarchy

DIS35WVW: Primary cutaneous T-cell lymphoma

DIS5OHQF: Primary cutaneous peripheral T-cell lymphoma not otherwise specified

Disease Identifiers

MONDO ID

MONDO_0019476

MESH ID

D016411

UMLS CUI

C0079774

MedGen ID

38240

Orphanet ID

86885

SNOMED CT ID

109977009

General Information of Disease (ID: DIS5OHQF)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 10 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fludarabine	DMVRLT7	Approved	Small molecular drug	[1]
Lenalidomide	DM6Q7U4	Approved	Small molecular drug	[2]
Mycophenolate mofetil	DMPQAGE	Approved	Small molecular drug	[3]
Mycophenolic acid	DMRBMAU	Approved	NA	[4]
Pralatrexate	DMAO80I	Approved	Small molecular drug	[5]
Rituximab	DM1YVZT	Approved	Antibody	[4]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[6]
Tacrolimus	DMZ7XNQ	Approved	Small molecular drug	[7]
Thalidomide	DM70BU5	Approved	Small molecular drug	[8]
Vidarabine	DM0N85H	Approved	Small molecular drug	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PDX-101	DM6OC53	Phase 2	Small molecular drug	[10]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 26 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALK	TTPMQSO	Limited	Biomarker	[11]
ITK	TT3C80U	Limited	Biomarker	[12]
MME	TT5TKPM	Limited	Biomarker	[13]
NCAM1	TTVXPHT	Limited	Biomarker	[14]
SYK	TT2HUPM	Limited	Biomarker	[12]
TCL1A	TTUKRDV	Limited	Genetic Variation	[15]
TNFRSF8	TT2GM5R	Limited	Biomarker	[16]
CD52	TTQT5S9	Disputed	Altered Expression	[17]
ATM	TTKBM7V	Strong	Biomarker	[18]
B2M	TTY7FKA	Strong	Altered Expression	[19]
BCL6	TTC9YX5	Strong	Genetic Variation	[20]
CD28	TTQ13FT	Strong	Genetic Variation	[21]
CD37	TTFCW29	Strong	Altered Expression	[22]
CD58	TT5KSBY	Strong	Biomarker	[23]
DNMT3A	TTJUALD	Strong	Biomarker	[24]
FYN	TT2B9KF	Strong	Biomarker	[23]
GATA3	TT45KOB	Strong	Biomarker	[25]
HDC	TTV9GOF	Strong	Biomarker	[26]
MS4A1	TTUE541	Strong	Biomarker	[27]
NAPRT	TTVR1FW	Strong	Altered Expression	[28]
RHOA	TTP2U16	Strong	Genetic Variation	[24]
TBX21	TTNF9PH	Strong	Genetic Variation	[25]
TRB	TT84HCW	Strong	Altered Expression	[29]
TRBC1	TT1DHW2	Strong	Altered Expression	[29]
CCR4	TT7HQD0	Definitive	Biomarker	[30]
FER	TTRA9G0	Definitive	Genetic Variation	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 26 DTT(s)

This Disease Is Related to 34 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
TET2	OTKKT03T	Limited	Genetic Variation	[32]
CD79A	OTOJC8DV	Disputed	Biomarker	[33]
LBH	OT87AT1X	moderate	Biomarker	[34]
CLEC10A	OTD8HQT6	Strong	Biomarker	[35]
DCTN3	OTQOSUES	Strong	Biomarker	[36]
DOK2	OTIJ38UF	Strong	Biomarker	[37]
DUSP22	OTEZ3U85	Strong	Genetic Variation	[38]
DYNC1H1	OTD1KRKO	Strong	Biomarker	[36]
GLIS2	OTOUUV1X	Strong	Biomarker	[39]
HPR	OTXSC9UB	Strong	Biomarker	[40]
IDH2	OTTQA4PB	Strong	Genetic Variation	[41]
IL2RG	OTRZ3OMY	Strong	Altered Expression	[12]
IRF4	OT1DHQ1P	Strong	Altered Expression	[42]
ISCU	OTSW6DQP	Strong	Biomarker	[35]
KRT20	OT4RB40L	Strong	Biomarker	[27]
MYO1F	OTOAV4AR	Strong	Biomarker	[43]
NAPSA	OT6F8IAL	Strong	Altered Expression	[44]
NECTIN2	OTIE0W6O	Strong	Biomarker	[45]
POLK	OTKZ38JH	Strong	Genetic Variation	[46]
PWWP3A	OTXQVL4U	Strong	Altered Expression	[42]
RHOJ	OTWI65OA	Strong	Biomarker	[47]
RHOV	OTW4N3QN	Strong	Biomarker	[48]
RPL18A	OTKBMVCX	Strong	Biomarker	[49]
SKAP1	OTD4ZKAL	Strong	Biomarker	[37]
SMTNL1	OT8F009J	Strong	Genetic Variation	[18]
STAT5B	OTZVPEBT	Strong	Genetic Variation	[50]
STK10	OTC33Y2F	Strong	Genetic Variation	[51]
STX11	OTHFRSFP	Strong	Biomarker	[52]
TCL1B	OT4CSO39	Strong	Genetic Variation	[15]
TCOF1	OT4BOYTM	Strong	Biomarker	[53]
TIA1	OTGPN3P8	Strong	Biomarker	[54]
TMOD1	OTTRYF9Y	Strong	Biomarker	[55]
TSPYL2	OTGGW2EF	Strong	Biomarker	[56]
CHP1	OTHTXN1A	Definitive	Biomarker	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 34 DOT(s)

References

1	Fludarabine FDA Label
2	Lenalidomide FDA Label
3	Mycophenolate mofetil FDA Label
4	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
5	Pralatrexate FDA Label
6	Romidepsin FDA Label
7	Tacrolimus FDA Label
8	Thalidomide FDA Label
9	Vidarabine FDA Label
10	Belinostat FDA Label
11	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.Ann Hematol. 2018 Jul;97(7):1241-1250. doi: 10.1007/s00277-018-3288-7. Epub 2018 Mar 16.
12	Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral Tcell lymphoma expressing the ITKSYK fusion gene.Int J Oncol. 2019 Nov;55(5):1077-1089. doi: 10.3892/ijo.2019.4882. Epub 2019 Sep 20.
13	Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.Br J Haematol. 2009 Mar;144(5):696-704. doi: 10.1111/j.1365-2141.2008.07534.x. Epub 2008 Dec 12.
14	Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia.Am J Surg Pathol. 2015 Jan;39(1):1-12. doi: 10.1097/PAS.0000000000000312.
15	Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization.Am J Clin Pathol. 2008 Aug;130(2):178-85. doi: 10.1309/PNXUKA1CFJMVGCN1.
16	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.Eur J Haematol. 2020 Mar;104(3):251-258. doi: 10.1111/ejh.13368. Epub 2020 Jan 10.
17	Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.J Clin Pathol. 2008 Nov;61(11):1160-7. doi: 10.1136/jcp.2008.055335. Epub 2008 Aug 28.
18	Concurrent Mutations in ATM and Genes Associated with Common Chain Signaling in Peripheral T Cell Lymphoma.PLoS One. 2015 Nov 4;10(11):e0141906. doi: 10.1371/journal.pone.0141906. eCollection 2015.
19	Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.Oncol Lett. 2019 Aug;18(2):1415-1423. doi: 10.3892/ol.2019.10410. Epub 2019 May 30.
20	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.Int J Hematol. 2017 Apr;105(4):465-469. doi: 10.1007/s12185-016-2159-z. Epub 2016 Dec 5.
21	Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.Leukemia. 2016 May;30(5):1062-70. doi: 10.1038/leu.2015.357. Epub 2015 Dec 31.
22	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8.
23	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.Nat Genet. 2014 Feb;46(2):166-70. doi: 10.1038/ng.2873. Epub 2014 Jan 12.
24	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.
25	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.
26	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.Int J Hematol. 2019 Feb;109(2):175-186. doi: 10.1007/s12185-018-2560-x. Epub 2018 Nov 14.
27	CD20-positive primary nasal peripheral T-cell lymphoma: An analysis of one case and review of the literature.Cytometry B Clin Cytom. 2020 Jul;98(4):348-354. doi: 10.1002/cyto.b.21852. Epub 2019 Nov 4.
28	Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.
29	A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.Blood. 1996 Feb 15;87(4):1416-22.
30	Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1456-1460. doi: 10.1111/jdv.14797. Epub 2018 Jan 31.
31	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.Biochem Biophys Res Commun. 2018 Oct 12;504(4):749-752. doi: 10.1016/j.bbrc.2018.09.019. Epub 2018 Sep 11.
32	Identification of cell-type-specific mutations in nodal T-cell lymphomas.Blood Cancer J. 2017 Jan 6;7(1):e516. doi: 10.1038/bcj.2016.122.
33	Peripheral T-cell lymphoma with extensive dendritic cell network mimicking follicular dendritic cell tumor: a case report with pathologic, immunophenotypic, and molecular findings.Am J Clin Pathol. 2006 Aug;126(2):230-4. doi: 10.1309/Q1YK-AU1X-XEN3-NVKQ.
34	Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.Curr Top Med Chem. 2019;19(3):223-241. doi: 10.2174/1568026619666190122144949.
35	Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes.Am J Pathol. 1988 Jul;132(1):1-5.
36	ins(6;11) in a case of peripheral T-cell lymphoma.Cancer Genet Cytogenet. 1987 Aug;27(2):367-9. doi: 10.1016/0165-4608(87)90021-5.
37	Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.Am J Surg Pathol. 2014 Oct;38(10):1349-59. doi: 10.1097/PAS.0000000000000309.
38	Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.Oncotarget. 2016 Oct 18;7(42):68734-68748. doi: 10.18632/oncotarget.11930.
39	Deregulated expression of NKL homeobox genes in T-cell lymphomas.Oncotarget. 2019 May 14;10(35):3227-3247. doi: 10.18632/oncotarget.26929. eCollection 2019 May 14.
40	Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.Exp Biol Med (Maywood). 2017 Jun;242(11):1178-1184. doi: 10.1177/1535370217706952. Epub 2017 Apr 21.
41	RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment.Exp Mol Pathol. 2019 Oct;110:104294. doi: 10.1016/j.yexmp.2019.104294. Epub 2019 Aug 5.
42	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.J Cancer. 2017 Mar 29;8(6):1018-1024. doi: 10.7150/jca.17358. eCollection 2017.
43	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114. Epub 2017 Jan 6.
44	Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
45	Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).Haematologica. 2017 Sep;102(9):e356-e359. doi: 10.3324/haematol.2017.168203. Epub 2017 Jun 28.
46	Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma.Fam Cancer. 2019 Jan;18(1):113-119. doi: 10.1007/s10689-018-0099-x.
47	Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression.Genes Chromosomes Cancer. 2002 Mar;33(3):243-51. doi: 10.1002/gcc.10021.
48	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.
49	Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas.Mod Pathol. 2019 Feb;32(2):216-230. doi: 10.1038/s41379-018-0130-7. Epub 2018 Sep 11.
50	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.Haematologica. 2020 Jan 31;105(2):435-447. doi: 10.3324/haematol.2019.216986. Print 2020.
51	STK10 missense mutations associated with anti-apoptotic function.Oncol Rep. 2013 Oct;30(4):1542-8. doi: 10.3892/or.2013.2605. Epub 2013 Jul 9.
52	STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas.Cancer Sci. 2015 Oct;106(10):1455-62. doi: 10.1111/cas.12742. Epub 2015 Aug 13.
53	Recombinative events of the T cell antigen receptor delta gene in peripheral T cell lymphomas.J Clin Invest. 1991 Feb;87(2):666-72. doi: 10.1172/JCI115044.
54	Composite lymphoma of peripheral T-cell lymphoma and Hodgkin lymphoma, mixed cellularity type; pathological and molecular analysis.Pathol Int. 2017 Apr;67(4):194-201. doi: 10.1111/pin.12515. Epub 2017 Feb 13.
55	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma.Blood. 2012 Aug 9;120(6):1274-81. doi: 10.1182/blood-2012-01-405555. Epub 2012 Jun 27.
56	Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.Clin Cancer Res. 2013 Jun 1;19(11):3095-104. doi: 10.1158/1078-0432.CCR-13-0109. Epub 2013 Apr 15.